Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399507 | 0.86 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1003534 | 0.83 | MEN1 (0.31) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL17457130 | 0.80 | BLM (0.34) | — | |
| SCHEMBL25687679 | 0.79 | KDM4E (0.32) | LMNAALDH1A1 | |
| SCHEMBL319857 | 0.78 | MEN1 (0.35) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL332512 | 0.78 | CA12 (0.36) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL24101 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL246225 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL641554 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL10384650 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738648-B2 | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-08-22 | — | — | US | disclosed |
| US-20160159804-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2245023-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-8071797-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | disclosed |
| CN-101910145-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2010-12-08 | — | — | CN | disclosed |
| EP-2245023-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009101022-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | WO | disclosed |
| US-20090208449-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | MED1, ZC3HAV1, BET1 | MEN1 2274/4885KMT2A 1154/4885HTT 3893/4885 |
| US-20160159804-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | MEN1 3983/4885KMT2A 1390/4885HTT 4367/4885 |
| US-20090208449-A1 | Heterocyclic antiviral compounds | EIF2AK2, HCCS, RTF2 | MEN1 4756/4885KMT2A 3411/4885HTT 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.